| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 09/14/2006 | US20060205763 For therapy and prophylaxis of cardiovascular diseases, diabetes, diabetes- associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and central nervous system disorders |
| 09/14/2006 | US20060205762 For therapy and prophylaxis of cardiovascular diseases, diabetes, diabetes- associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and central nervous system disorders |
| 09/14/2006 | US20060205750 Cardiovascular disorders; central nervous system disorders; metabolic diseases; therapy for eating disorders; trans-2-(2-fluorophenyl)-8-[3'-oxospiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-yl]purine |
| 09/14/2006 | US20060205744 Fused heterocyclic derivatives as ppar modulators |
| 09/14/2006 | US20060205734 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 09/14/2006 | US20060205726 e.g. 2-(2-{3-acetoxy-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester; microsomal triglyceride transfer protein inhibitor in small intestine; antihyperlipidemic, antidiabetic agent; arteriosclerosis, coronary artery diseases, obesity |
| 09/14/2006 | US20060205723 5-(Substituted oxazolyl- or thiazolyl-ethoxy)indaneacetic acid derivatives, used in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases |
| 09/14/2006 | US20060205721 3-(Phenyl),5-(3-carmoylphenyl)-amino)-3H-V-triazolo(4,5-D)pyrimidine; bipolar disorder, antidepressants; antidiabetic agents; Alzheimer's disease; blood disorders; dementia; parkinson's disease; neurodegenerative diseases; genetic disorders; muscular disorders; antiinflammatory/anticarcinogenic agents |
| 09/14/2006 | US20060205720 such as 2-(4-chloro-phenyl)-5-cyclopentyl-1-(2-fluoro-phenyl)-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one; for treatment of eating disorders and psychological disorders |
| 09/14/2006 | US20060205715 6-(8-Pentylamino-5,6,7,8-tetrahydro-naphthalen-2-yloxy)-nicotinamide; increase metabolic energy consumption, and reduction of weight; obesity, antidiabetic agent, eating disorders; antidepressant, anxiolytic agent |
| 09/14/2006 | US20060205713 Antidiabetic agents; disease of glucose tolerance; insulin resistance; obesity; dyslipidemia; metabolic disorders; liver disorders; [4-(6-Phenethyloxy-pyridazin-3-yl)piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone; stearoyl-CoA desaturase modulators |
| 09/14/2006 | US20060205711 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| 09/14/2006 | US20060205710 Spiroazacyclic compounds as monoamine receptor modulators |
| 09/14/2006 | US20060205708 such as 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}oxime; phosphodiesterase IV inhibitors |
| 09/14/2006 | US20060205675 Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
| 09/14/2006 | US20060205665 Non-basic amino acid sequence transporter peptide conjugated to biological effector; translocation across the membrane of eukaryotic cells |
| 09/14/2006 | US20060205659 Peptide radical having 5-25 amino acids with its N-terminus capped with a monoester of fumaric acid; used to treat autoimmune diseases, mitochondrial diseases, and NF-kappaB mediated diseases and in transplantation medicine |
| 09/14/2006 | US20060205018 Polypeptides which have zinc metalloprotease activities and are referred to as IGS5, and polynucleotides encoding such polypeptides; use in therapy |
| 09/14/2006 | US20060204593 Superoxide anion decomposing agent |
| 09/14/2006 | US20060204577 Pharmaceutical Compositions of Drugs and Neutralized Acidic Polymers |
| 09/14/2006 | US20060204518 Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
| 09/14/2006 | US20060204517 Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
| 09/14/2006 | DE102005010770A1 Producing 1,4-diphenylazetidinone derivatives useful as cholesterol resorption inhibitors from protected beta-substituted amino amides comprises using a quaternary phosphonium salt catalyst |
| 09/14/2006 | CA2601985A1 A synergistically heat stable oil media having eicosa pentaenoic acid (epa) and do-cosa hexaenoic acid (dha) |
| 09/14/2006 | CA2599376A1 Roflumilast for the treatment of diabetes mellitus |
| 09/14/2006 | CA2599250A1 Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives as antidiabetic compounds |
| 09/13/2006 | EP1700606A1 Therapies for chronic renal failure using one or more integrin antagonists |
| 09/13/2006 | EP1700604A1 Alga extract and sugar hydrolase inhibitor containing the same |
| 09/13/2006 | EP1699796A1 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 09/13/2006 | EP1699761A1 Cb1 modulator compounds |
| 09/13/2006 | EP1699760A2 Anti-hypercholesterolemic compounds |
| 09/13/2006 | EP1699759A1 Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| 09/13/2006 | EP1699758A1 Diphenylazetidinone derivates processing cholesterol absorption inhibitory activity |
| 09/13/2006 | EP1699490A2 Medical lipolysis of fat accumulations |
| 09/13/2006 | EP1699476A1 Method for preventing and treating diabetes using dg119 |
| 09/13/2006 | EP1699467A1 Aminoglycoside antibiotics for use as vap-1/ssao inhibitors |
| 09/13/2006 | EP1699452A2 Use of statins for the treatment of metabolic syndrome |
| 09/13/2006 | EP1699449A1 Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
| 09/13/2006 | EP1699448A2 Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid |
| 09/13/2006 | EP1613326B1 (3-{3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl-pyrimidin-2-yl)-amino]-propoxy}-phenyl)-acetic acid and related compounds as modulators of ppars and methods of treating metabolic disorders |
| 09/13/2006 | EP1532145B1 Pyrazole compositions useful as inhibitors of gsk-3 |
| 09/13/2006 | EP1513942B1 Galactosyl isomalt, method for production and use thereof |
| 09/13/2006 | EP1497274B1 Terphenyl derivatives, preparation thereof, compositions containing same |
| 09/13/2006 | EP1483257B1 Quinazoline compounds useful in therapy |
| 09/13/2006 | EP1404685B1 Aryl boronic acids for treating obesity |
| 09/13/2006 | EP1392684B1 Thiazole compounds useful as inhibitors of protein kinases |
| 09/13/2006 | EP1389206B1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 09/13/2006 | EP1305635B1 Methods to identify compounds that modulate rage |
| 09/13/2006 | EP1237888B1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 09/13/2006 | EP1230215B1 Pyrrole derivatives as phosphodiesterase vii inhibitors |
| 09/13/2006 | EP1218358B1 Therapeutic quinazoline compounds |
| 09/13/2006 | EP0987957B1 Method for administering a viable microorganism composition to poultry |
| 09/13/2006 | EP0917462B1 Cell adhesion inhibitors |
| 09/13/2006 | CN1832959A Polyethelene glycol link glp-1 compounds |
| 09/13/2006 | CN1832949A Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| 09/13/2006 | CN1832934A Benzoxazepine-based compound |
| 09/13/2006 | CN1832926A 6-(2,2,2-trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist |
| 09/13/2006 | CN1832745A 2-'4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatement of obesity |
| 09/13/2006 | CN1832740A Indol-5 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 09/13/2006 | CN1832739A Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 09/13/2006 | CN1832738A Indol-6 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 09/13/2006 | CN1832728A Process for producing drug ultramicroparticle and apparatus therefor |
| 09/13/2006 | CN1831012A Immunological adjuvant with immunity vegulating agent for treating and preventing diabetic from insulin-dependent |
| 09/13/2006 | CN1830961A Process for preparing medicine for treating glycuresis, application of its pharmaceutical prepn. |
| 09/13/2006 | CN1830479A Earth ginseng sugar reducing health-care food |
| 09/13/2006 | CN1830464A Application of olecranone bean extraction in preparation of food for preventing and treating obesity and type II diabetes |
| 09/13/2006 | CN1830461A Safflower injection and its preparation method |
| 09/13/2006 | CN1830455A Preparation method of multi-kind micro-element injection |
| 09/13/2006 | CN1830453A Preparation method of vitamin medicinal composition |
| 09/13/2006 | CN1830431A Preparation method of potassium magnesium aspartate freeze dried powder injection |
| 09/13/2006 | CN1830427A Preparation method of sodium ferulate freeze dried powder injection |
| 09/13/2006 | CN1830327A Manufacturing method of wilsonii and wolfberry fruit carbonated beverage |
| 09/13/2006 | CN1830298A Health-care vermicelli with wolfberry root bark |
| 09/13/2006 | CN1830284A Tea and its preparation method |
| 09/13/2006 | CN1830282A Make-up of body fat reducing peony tea and its preparation method |
| 09/13/2006 | CN1830279A Dried orange peel health-care tea |
| 09/13/2006 | CN1274717C Immune suppression fusion protein, its coded nucleic acid and application |
| 09/13/2006 | CN1274715C Memno peptides, a process for their preparation and their use |
| 09/13/2006 | CN1274690C Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as active ingredient |
| 09/13/2006 | CN1274684C Bee glue flavone extract preparation method, pharmaceutical preparation and its new medical uses |
| 09/13/2006 | CN1274676C Quinoline and quinazoline derivatives |
| 09/13/2006 | CN1274669C Fluorobenzamides suitable for the treatment of alzheimer's disease or senile dementia |
| 09/13/2006 | CN1274668C Salts of nateglinide |
| 09/13/2006 | CN1274655C Novel 3-aryl-2,5-dihydroxy-1,4-benzoquinone derivatives, their preparation method and pharmaceutical compositions containing same |
| 09/13/2006 | CN1274361C Soybean peptide, its preparation and application |
| 09/13/2006 | CN1274347C Organic biological preparation for preventing and curing selenium deficiency disease |
| 09/13/2006 | CN1274341C Medicine for treating diabetes |
| 09/13/2006 | CN1274339C Anqi preparation, its preparation method and uses |
| 09/13/2006 | CN1274314C Health care food for defatting |
| 09/13/2006 | CN1274302C Blood fat reducing composition containing avatatin and its use |
| 09/13/2006 | CN1274301C Application of alpha benzyl, beta benzyl and gamma butyrolactone for preparing medicine of lowering blood sugar |
| 09/13/2006 | CN1274300C Combination of medication in use for improving dissolution of curcumin and bioavailability as well as preparation method |
| 09/12/2006 | US7105682 Substituted amine derivatives and methods of use |
| 09/12/2006 | US7105673 Cardioprotective phosphonates and malonates |
| 09/12/2006 | US7105671 2-Substituted phenyl,3-polar ring,N-heroaromatic propion-amides, e.g., 1-(2-(3,4-Dichlorophenyl)-3-(tetrahydro-furan-2-yl)-propionyl)-3- methylurea; antidiabetic agents; increase the flux of glucose metabolism in beta-cells and hepatocytes |
| 09/12/2006 | US7105665 Compound for treatment of diarrhea, nervous system disorders such as Alzheimers and asthma in mammals |
| 09/12/2006 | US7105556 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| 09/12/2006 | US7105552 Treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis. |
| 09/12/2006 | US7105548 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| 09/12/2006 | US7105546 Useful for treating or preventing neuronal damage associated with neurological diseases |